Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

Blood cancer journal·2026
Same author

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same author

Genomics reboot for secondary myelofibrosis.

Blood·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Extended Cancer Spectrum in Adults With Telomere Biology Disorders: Insights From a 113-Patient Single-Center Cohort.

American journal of hematology·2026

Related Experiment Video

Updated: Jun 11, 2025

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.4K

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.

Zhuoer Xie1,2, Jenna Fernandez1, Terra Lasho1

  • 1Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Blood
|October 1, 2024
PubMed
Summary

High-dose intravenous ascorbic acid did not show efficacy in treating TET2 mutant clonal cytopenia. This phase 2 trial found no responses in eligible patients by week 20.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Related Experiment Videos

Last Updated: Jun 11, 2025

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.4K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Clonal cytopenias, particularly those with TET2 mutations, represent a significant challenge in hematologic oncology.
  • Investigating novel therapeutic strategies for these conditions is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of high-dose intravenous (IV) ascorbic acid in patients with TET2-mutated clonal cytopenias.
  • To assess the safety and tolerability of this treatment regimen.

Main Methods:

  • A phase 2 clinical trial was conducted.
  • Ten patients with TET2 mutant clonal cytopenia were enrolled.
  • High-dose IV ascorbic acid was administered.
  • Response assessment was performed using International Working Group Myelodysplasia Syndromes/Neoplasms criteria at week 20.

Main Results:

  • Eight out of 10 patients were eligible for response assessment.
  • No responses were observed in any eligible patients at week 20.
  • The study did not report specific adverse events but focused on response rates.

Conclusions:

  • High-dose IV ascorbic acid demonstrated no efficacy in treating TET2 mutant clonal cytopenia in this phase 2 trial.
  • Further research may be needed to explore alternative therapies for this patient population.